Track Repatha price changes
Subscribe for DrugPrice updates by email. No spam, unsubscribe anytime.
Why Repatha Costs $757.00 Per Claim
Repatha (Evolocumab) is used to treat high cholesterol. According to CMS Medicare Part D spending data, the program spent $2.6B on this drug, covering 398,000 beneficiaries across 3,420,000 claims.
This drug is currently protected by patents expiring Aug 27, 2029. Until patent protection ends, no generic version can enter the market, which limits price competition. Once generics become available, the price typically drops 80-95%.
Spending on Repatha increased by +24.6% year-over-year, driven by increased utilization among Medicare beneficiaries.
Price Breakdown
Drug Details
Frequently Asked Questions
Repatha (Evolocumab) costs an average of $757.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $6,505.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Repatha averages $757.00 per Medicare Part D claim — roughly equivalent to a 30-day supply for most patients on standard dosing. Without insurance, expect higher cash-pay prices unless you use a discount program (GoodRx, SingleCare, manufacturer copay assistance). With Medicare or commercial insurance, your out-of-pocket cost depends on your plan's formulary tier and deductible status.
A typical 30-day supply of Repatha reflects in our Medicare Part D average of $757.00 per claim. No generic is available yet, so cost remains at brand-name pricing. Cash-pay prices vary by pharmacy — comparison shopping (or using GoodRx coupons) often saves 20-50% off the listed price.
Most commercial insurance plans and Medicare Part D plans cover Repatha, but coverage varies by formulary tier. Repatha is often Tier 2 or Tier 3 on most formularies, meaning a higher copay than generic alternatives. Some plans require prior authorization or step therapy. Check your plan's formulary or call the number on your insurance card to confirm.
Several options for cash-pay patients: (1) Manufacturer patient assistance programs — the manufacturer may offer copay cards or free-drug programs for income-qualified patients; (2) Discount programs like GoodRx, SingleCare, or RxSaver typically save 20-80% off the cash price; (3) Mark Cuban's Cost Plus Drugs offers transparent generic pricing if a generic is available; (4) 340B-eligible community health centers offer drugs at federally negotiated discounts. Patient assistance programs are the primary affordability path while no generic is available.
Repatha is still under patent protection until Aug 27, 2029, giving the manufacturer market exclusivity. Once the patent expires, generics enter the market and prices typically fall 80-95% within 1-2 years.
No, Repatha is currently brand-only. Patent protection expires Aug 27, 2029, after which generic versions may enter the market.
Medicare Part D spent $2.6B on Repatha, covering 398,000 beneficiaries across 3,420,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Check manufacturer patient assistance programs for potential savings. You can also compare prices at different pharmacies, use prescription discount programs (GoodRx, SingleCare, Cost Plus Drugs), or ask your doctor about therapeutic alternatives in the same drug class.
Reading Repatha's Medicare Pricing
Repatha averages $757.00 per Part D claim — a high-cost brand medication, well above the commodity-generic range but below the specialty/biologic tier. A price in this band usually signals an on-patent brand with no generic equivalent, or a brand that holds share through prescriber and patient preference even where a generic exists. For high cholesterol, the gap between this price and a same-class alternative is where the real savings conversation tends to live.
As a Medicare line item, Repatha is enormous: $2.6B in total Part D spending across 3,420,000 claims for 398,000 beneficiaries. At that scale the total is a product of both reach and price — a drug this widely prescribed at this cost is exactly the kind of molecule that draws CMS price-negotiation attention and PBM formulary leverage. The per-beneficiary figure, roughly $7K a year, is what translates the aggregate into an individual cost picture.
No generic competes with Repatha yet — patent protection runs to Aug 27, 2029, the date that matters most for its future price. Until then the savings levers are narrower: manufacturer copay assistance for those who qualify, discount-card pricing on cash-pay fills, and therapeutic substitution to a cheaper in-class option for high cholesterol where one exists. The structural price drop arrives with generic entry, which historically pulls prices down 80–95% within a year or two of the patent cliff.
Every figure here comes from the CMS Medicare Part D Drug Spending dashboard, which reports what the program paid — not the cash price at a retail pharmacy and not a patient's out-of-pocket cost. List prices also overstate the real economics: manufacturers pay confidential rebates to pharmacy benefit managers, so the net price plans actually pay is often well below the sticker. Treat $757.00 as a consistent Medicare-program benchmark for Repatha, useful for comparing drugs on the same basis, rather than the price any one patient will see at the counter.
Related
Compare costs for other high cholesterol medications
Compare 8 drugs in the Statins (Cholesterol-Lowering) class
See every Amgen drug tracked by Medicare Part D
Top prescription drugs by Medicare spending
Drugs losing patent protection soon
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.